TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8857434

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (6 mu g kg‐1 min‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no dobutamine)
Number of subjects: 16
Study: 1627200

Group type: EXPERIMENTAL
Intervention: 2% sertaconazole dermatological cream
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 5 other commercially available antimycotics (econazole, ketoconazole, bifonazole, clotrimazole, miconazole)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Excipient of the cream without sertaconazole
Number of subjects: 78

Group type: COMPARATOR
Intervention: 2% sertaconazole in vaseline
Number of subjects: 78
Study: 6373426

Group type: EXPERIMENTAL
Intervention: Maximized metabolic control (multiple insulin injections daily or insulin pumps)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard control (one or more injections of insulin daily)
Number of subjects: 32
Study: 30169797

Group type: EXPERIMENTAL
Intervention: Culturally targeted Courage to Quit (CTQ-CT) smoking cessation treatment
Number of subjects: 345

Group type: COMPARATOR
Intervention: Standard Courage to Quit (CTQ) smoking cessation intervention
Number of subjects: 345
Study: 27390305

Group type: EXPERIMENTAL
Intervention: LigaSure Small Jaw®
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional neck dissection
Number of subjects: 41
Study: 26301923

Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Telephone information
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Face-to-face information
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Control group (no briefing)
Number of subjects: 1676
Study: 24225668

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21652220

Group type: EXPERIMENTAL
Intervention: Doxercalciferol capsules (conversion factors: 0.5, 1.0, 1.5 times the current paricalcitol dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxercalciferol capsules (conversion factors: 1.0, 1.5, 2.0 times the current doxercalciferol injection dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxercalciferol capsules
Number of subjects: 0
Study: 21039051

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Knowledge about mammography
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Awareness of mammogram frequency
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Perception of mammogram side effects
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Early detection knowledge
Number of subjects: 86
Study: 17554581

Group type: EXPERIMENTAL
Intervention: Oral risedronate 2.5 mg/day for 6 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: No osteoactive drug (Control)
Number of subjects: 43
Study: 15893211

Group type: EXPERIMENTAL
Intervention: Making a risk estimate prior to receiving risk information
Number of subjects: 356

Group type: COMPARATOR
Intervention: Not making a risk estimate prior to receiving risk information
Number of subjects: 356
Study: 12584837

Group type: EXPERIMENTAL
Intervention: Fuzheng Qubi Decoction (FZQBD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Western medicine combination therapy
Number of subjects: 30
Study: 9849278

Group type: EXPERIMENTAL
Intervention: Lithotomy positioning (n = 12)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (n = 12)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: General anaesthesia in the supine position (n = 12)
Number of subjects: 36
Study: 8181590

Group type: EXPERIMENTAL
Intervention: Pre-operative intra-arterial chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More effective drugs and less demanding regimens
Number of subjects: 0
Study: 2678857

Group type: EXPERIMENTAL
Intervention: Transversalis fascia-Cooper ligament (McVay) repair
Number of subjects: 171

Group type: COMPARATOR
Intervention: Transversalis fascia-ileopubic tract (Ottsen) repair
Number of subjects: 171
Study: 138560

Group type: EXPERIMENTAL
Intervention: Minocycline 50 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetracycline 250 mg twice daily
Number of subjects: 0
Study: 31722700

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis (AMP) discontinued within 24 hours after surgery
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Antimicrobial prophylaxis (AMP) discontinued within 24-48 hours after surgery
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Both groups (24h and 48h)
Number of subjects: 1000
Study: 28566393

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite coated acetabular component (group 1)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Macrotexture acetabular component (group 2)
Number of subjects: 302
Study: 25912621

Group type: EXPERIMENTAL
Intervention: Formula scoring (FS)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Don't know option (DKO)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Number-right (NR) scores
Number of subjects: 337
Study: 24289591

Group type: EXPERIMENTAL
Intervention: Recall letter for a repeat smear
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Registered letter
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Short messages services (SMS)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Phone calls
Number of subjects: 1000
Study: 21738077

Group type: EXPERIMENTAL
Intervention: 7.5 g/day TU-025
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 12.5 g/day TU-025
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 19321019

Group type: EXPERIMENTAL
Intervention: Cognitive approaches to understanding and treating positive psychotic symptoms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive appraisal dimensions and reasoning styles (inferential confusion, cognitive slippage, fantasy proneness, perceptual immersion).
Number of subjects: 0
Study: 16500490

Group type: EXPERIMENTAL
Intervention: Contrast echocardiography (CE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gated single photon emission computed tomography (SPECT)
Number of subjects: 36
Study: 14634170

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste and mouthrinse
Number of subjects: 6

Group type: COMPARATOR
Intervention: No fluoride toothpaste and mouthrinse
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In vivo fluoride release
Number of subjects: 6

Group type: COMPARATOR
Intervention: In vitro fluoride release
Number of subjects: 6
Study: 10690824

Group type: EXPERIMENTAL
Intervention: Bulbar conjunctival blood column (BCBC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palpebral conjunctival hue (PCH)
Number of subjects: 0
Study: 9322458

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Droperidol (20 micrograms/kg)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 158

Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 158
Study: 8095127

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Famotidine (20 mg twice daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nizatidine (150 mg twice daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study: 3555898

Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF)
Number of subjects: 45
Study: 31538372

Group type: EXPERIMENTAL
Intervention: Osmotic-Release Oral System Methylphenidate (OROS‐MPH)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 29414612

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local Infiltration Analgesia (LIA)
Number of subjects: 40
Study: 26470053

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 272

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 272
Study: 24226490

Group type: EXPERIMENTAL
Intervention: Maintaining cuff pressure at 60 cmH2O in PSV group
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention in cuff pressure in PSV group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Maintaining cuff pressure at 60 cmH2O (all ventilation modes)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention in cuff pressure (all ventilation modes)
Number of subjects: 120
Study: 22171794

Group type: EXPERIMENTAL
Intervention: REDUSTIM(®) device (alternate low frequency electromagnetic fields and controlled micropressure) for 12 sessions over 6 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: REDUSTIM(®) device
Number of subjects: 28
Study: 19006068

Group type: EXPERIMENTAL
Intervention: Real ultrasound (US) treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham ultrasound (US) treatment
Number of subjects: 12
Study: 17199580

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 265

Group type: COMPARATOR
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 265
Study: 16261462

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg followed immediately by propofol LCT 2 mg.kg(‐1)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg followed by propofol LCT 2 mg.kg(‐1) 1 min later
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 2% Lidocaine 40 mg followed immediately by propofol LCT 2 mg.kg(‐1)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Propofol LCT 2 mg.kg(‐1) alone
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Propofol in a mixture of medium‐chain triglyceride (MCT) and LCT 2 mg.kg(‐1)
Number of subjects: 250
Study: 11895791

Group type: EXPERIMENTAL
Intervention: Anti-Helicobacter pylori treatment
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Molecular follow-up analysis
Number of subjects: 189

Group type: COMPARATOR
Intervention: Presence of molecular disease
Number of subjects: 189
Study: 9861141

Group type: EXPERIMENTAL
Intervention: Atropine premedication
Number of subjects: 30

Group type: COMPARATOR
Intervention: No atropine premedication (Control)
Number of subjects: 30
Study: 7725129

Group type: EXPERIMENTAL
Intervention: Participation in a demonstration project to improve patient care
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Demographic characteristics of community pharmacists
Number of subjects: 418
Study: 2547560

Group type: EXPERIMENTAL
Intervention: nedocromil sodium 4mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 10798

Group type: EXPERIMENTAL
Intervention: Solcoseryl and Proglumide (systematic preventive treatment)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No specific treatment (Control group)
Number of subjects: 68
Study: 30808512

Group type: EXPERIMENTAL
Intervention: d‐Nav Insulin Guidance System with health‐care professional support
Number of subjects: 181

Group type: COMPARATOR
Intervention: Health‐care professional support alone
Number of subjects: 181
Study: 28072863

Group type: EXPERIMENTAL
Intervention: 30mg/kg of oral azithromycin
Number of subjects: 247

Group type: COMPARATOR
Intervention: 50,000 units/kg of intramuscular benzathine penicillin
Number of subjects: 247
Study: 26264718

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) >20 mg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) (all doses)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hydrocortisone (HC) ≤20 mg/day
Number of subjects: 53
Study: 23794107

Group type: EXPERIMENTAL
Intervention: tolcapone (100 mg three times a day for 1 day and then 200 mg three times a day for 6 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 21183746

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 0
Study: 19758969

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nadroparin (70.4 IU/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dalteparin (78.6 IU/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 17
Study: 16679905

Group type: EXPERIMENTAL
Intervention: Vaseline gauze (VD)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Biobrane (BD)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Occlusive film dressing Barrier Flex (OD)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Equine collagen foil, Tissu Foil E (CD)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (uninjured skin)
Number of subjects: 33
Study: 15762391

Group type: EXPERIMENTAL
Intervention: Mixed model approach for assessment of interventions
Number of subjects: 0
Study: 11318058

Group type: EXPERIMENTAL
Intervention: Variation of the arm's mass distribution combined with prism adaptation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prism adaptation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulations of plane of motion, body posture, proprioceptive target, and proprioceptive experience during prism adaptation
Number of subjects: 0
Study: 9863076

Group type: EXPERIMENTAL
Intervention: Shuxuening (SXN) 120 mg three times daily
Number of subjects: 545

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Shuxuening (SXN)
Number of subjects: 545
Study: 8181219

Group type: EXPERIMENTAL
Intervention: tiapride (200 mg/die)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 3540084

Group type: EXPERIMENTAL
Intervention: Exercise training (activity group, n = 113)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (n = 111)
Number of subjects: 224
Study: 31876643

Group type: EXPERIMENTAL
Intervention: POC+PM
Number of subjects: 226

Group type: COMPARATOR
Intervention: POC
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Change Process Capability Questionnaire
Number of subjects: 226
Study: 30544449

Group type: EXPERIMENTAL
Intervention: Surgiflo Haemostatic Matrix (SHM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Absorbable Gelatin Sponge (AGS)
Number of subjects: 60
Study: 26956651

Group type: EXPERIMENTAL
Intervention: Home-based parenting intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard pediatric primary care
Number of subjects: 60
Study: 25275422

Group type: EXPERIMENTAL
Intervention: Cold pressor-induced pain during PASAT performance
Number of subjects: 72

Group type: COMPARATOR
Intervention: Painless room-temperature water immersion during PASAT performance
Number of subjects: 72
Study: 23838501

Group type: EXPERIMENTAL
Intervention: Topical diltiazem gel (2ml of 2% topical diltiazem gel)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 20965465

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1056

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1056
Study: 17899340

Group type: EXPERIMENTAL
Intervention: Eye-closure during retrieval
Number of subjects: 5

Group type: COMPARATOR
Intervention: No instructions during retrieval
Number of subjects: 5
Study: 17129308

Group type: EXPERIMENTAL
Intervention: Postoperative lavender oil aromatherapy (2 drops of 2% lavender oil with supplemental oxygen)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (supplemental oxygen with no lavender oil)
Number of subjects: 50
Study: 14664471

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA), 20 mg daily subcutaneous injections
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo for 30 months followed by GA
Number of subjects: 251
Study: 11094039

Group type: EXPERIMENTAL
Intervention: SR90107A/ORG31540 (5 mg once daily)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: SR90107A/ORG31540 (7.5 mg once daily)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: SR90107A/ORG31540 (10 mg once daily)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Dalteparin (100 IU/kg twice daily)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: SR90107A/ORG31540
Number of subjects: 453

Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: SR90107A/ORG31540 and Dalteparin
Number of subjects: 453
Study: 8747098

Group type: COMPARATOR
Intervention: Sugar ingestion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Candy or chocolate consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet-oriented treatment
Number of subjects: 0
Study: 2056362

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.05 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diazepam (0.25 mg/kg)
Number of subjects: 60
Study: 6624809

Group type: EXPERIMENTAL
Intervention: Picenadol (LY 150720), 25 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Meperidine, 100 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 29716398

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Context of treatment (research vs community)
Number of subjects: 52
Study: 30917811

Group type: EXPERIMENTAL
Intervention: 14-h Youth MHFA course
Number of subjects: 384

Group type: COMPARATOR
Intervention: 15-h Australian Red Cross Provide First Aid course
Number of subjects: 384
Study: 29083323

Group type: EXPERIMENTAL
Intervention: Dimethylguanidino valeric acid (DMGV) levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-procedure cardiometabolic parameters
Number of subjects: 0
Study: 26872366

Group type: EXPERIMENTAL
Intervention: Tapered-cuff endotracheal tube
Number of subjects: 109

Group type: COMPARATOR
Intervention: Spherical-cuff endotracheal tube (Control)
Number of subjects: 109
Study: 24598085

Group type: EXPERIMENTAL
Intervention: Restorative care service
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study: 22997340

Group type: EXPERIMENTAL
Intervention: Disrupted reconsolidation through extinction training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reactivation of conditioned fear memory
Number of subjects: 0
Study: 20812879

Group type: EXPERIMENTAL
Intervention: Pregabalin (300 and 450 mg/day)
Number of subjects: 2061
Study: 17659605

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg once daily
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg twice daily
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 15868384

Group type: EXPERIMENTAL
Intervention: Aprinocarsen (2 mg/kg continuous iv infusion on days 1-14, every 21 days) + Gemcitabine (1250 mg/m2 on days 1 and 8) + Cisplatin (80 mg/m2 on day 1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Gemcitabine (1250 mg/m2 on days 1 and 8) + Cisplatin (80 mg/m2 on day 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aprinocarsen + Gemcitabine + Cisplatin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Gemcitabine + Cisplatin
Number of subjects: 18
Study: 17109676

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 0.15 microg/kg/week
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 0.30 microg/kg/week
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 0.45 microg/kg/week
Number of subjects: 61
Study: 10506601

Group type: EXPERIMENTAL
Intervention: Induction therapy with AFM
Number of subjects: 425
Study: 8900778

Group type: EXPERIMENTAL
Intervention: Community Nursing Organization (CNO) model
Number of subjects: 0
Study: 1855763

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg once daily)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 6349715

Group type: EXPERIMENTAL
Intervention: WBC-depleted platelet concentrates (PC)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard pooled platelet concentrates (PC)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: WBC-depleted PC
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard PC
Number of subjects: 98
Study: 30957341

Group type: EXPERIMENTAL
Intervention: CAP + EUC
Number of subjects: 135

Group type: COMPARATOR
Intervention: EUC
Number of subjects: 135
Study: 30168228

Group type: EXPERIMENTAL
Intervention: Community-based 8-week exercise training programme (walking and activity increase with pedometer)
Number of subjects: 33

Group type: COMPARATOR
Intervention: General recommendations to walk more (Control group)
Number of subjects: 33
Study: 27069360

Group type: EXPERIMENTAL
Intervention: Puer tea extract (PTE) 3 g/day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 25043321

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (10 weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Basic body awareness therapy (BBAT) (10 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (single consultation with advice on physical activity)
Number of subjects: 62
Study: 22483196

Group type: EXPERIMENTAL
Intervention: Learning therapy (reading aloud and solving simple calculations)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 64
Study: 20128828

Group type: EXPERIMENTAL
Intervention: Flapless procedure
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional flap procedure
Number of subjects: 16
Study: 18094894

Group type: EXPERIMENTAL
Intervention: Oral contraceptive with placebo (levonorgestrel and ethinyl estradiol)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Oral contraceptive with estriol (levonorgestrel and ethinyl estradiol)
Number of subjects: 33
Study: 15809663

Group type: EXPERIMENTAL
Intervention: BMI < 18.5
Number of subjects: 49165

Group type: COMPARATOR
Intervention: BMI 18.5-21.9 (reference)
Number of subjects: 49165

Group type: EXPERIMENTAL
Intervention: BMI 22-24.9
Number of subjects: 49165

Group type: EXPERIMENTAL
Intervention: BMI 25.0-27.9
Number of subjects: 49165

Group type: EXPERIMENTAL
Intervention: BMI 28.0-29.9
Number of subjects: 49165

Group type: EXPERIMENTAL
Intervention: BMI 30.0-34.9
Number of subjects: 49165

Group type: EXPERIMENTAL
Intervention: BMI >= 35.0
Number of subjects: 49165